What Is Rigel Pharmaceuticals, Inc. (RIGL) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Rigel Pharmaceuticals, Inc.'s intrinsic value is estimated at a composite fair value of $41.38. Trading at $41.30, the stock is approaching fair value or slight overvaluation (implied return of +0.2%), as 8 of 12 models suggest limited further upside. Model dispersion is worth noting: ML-RIV targets $86.87 (+110.3%), versus Bayesian DCF at $10.37 (-74.9%). This +185.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About RIGL?
12 of 13 models are currently active for RIGL. Of these, 4 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates RIGL's intrinsic value at $10.37, implying -74.9% downside from the current price. See which stocks rank higher →
How Does RIGL Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, RIGL ranks #21 by Quality of Company score. CirclFi's QOC score of 8.6/10 evaluates 32 fundamental signals. A score of 8.6 places RIGL in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Rigel Pharmaceuticals, Inc.'s positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is RIGL a Value Trap?
CirclFi's Value Trap algorithm assigns RIGL a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Rigel Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Rigel Pharmaceuticals, Inc. earns a quality score of 8.6/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +185.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RIGL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RIGL's 12 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad